These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 9687511

  • 1. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.
    Perrotti D, Bonatti S, Trotta R, Martinez R, Skorski T, Salomoni P, Grassilli E, Lozzo RV, Cooper DR, Calabretta B.
    EMBO J; 1998 Aug 03; 17(15):4442-55. PubMed ID: 9687511
    [Abstract] [Full Text] [Related]

  • 2. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
    Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA, Calabretta B.
    Nat Genet; 2002 Jan 03; 30(1):48-58. PubMed ID: 11753385
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD.
    Exp Hematol; 1993 Oct 03; 21(11):1460-6. PubMed ID: 8405226
    [Abstract] [Full Text] [Related]

  • 4. BCR-ABL prevents c-jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CbetaII-dependent pathway.
    Perrotti D, Iervolino A, Cesi V, Cirinná M, Lombardini S, Grassilli E, Bonatti S, Claudio PP, Calabretta B.
    Mol Cell Biol; 2000 Aug 03; 20(16):6159-69. PubMed ID: 10913197
    [Abstract] [Full Text] [Related]

  • 5. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.
    Oncogene; 2002 Nov 21; 21(53):8075-88. PubMed ID: 12444544
    [Abstract] [Full Text] [Related]

  • 6. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
    Okuda K, Golub TR, Gilliland DG, Griffin JD.
    Oncogene; 1996 Sep 19; 13(6):1147-52. PubMed ID: 8808688
    [Abstract] [Full Text] [Related]

  • 7. Human POMp75 is identified as the pro-oncoprotein TLS/FUS: both POMp75 and POMp100 DNA homologous pairing activities are associated to cell proliferation.
    Bertrand P, Akhmedov AT, Delacote F, Durrbach A, Lopez BS.
    Oncogene; 1999 Aug 05; 18(31):4515-21. PubMed ID: 10442642
    [Abstract] [Full Text] [Related]

  • 8. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
    Chai SK, Nichols GL, Rothman P.
    J Immunol; 1997 Nov 15; 159(10):4720-8. PubMed ID: 9366395
    [Abstract] [Full Text] [Related]

  • 9. TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain.
    Prasad DD, Ouchida M, Lee L, Rao VN, Reddy ES.
    Oncogene; 1994 Dec 15; 9(12):3717-29. PubMed ID: 7970732
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

  • 11. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
    Nieborowska-Skorska M, Slupianek A, Skorski T.
    Oncogene; 2000 Aug 24; 19(36):4117-24. PubMed ID: 10962572
    [Abstract] [Full Text] [Related]

  • 12. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW, Ren R.
    Oncogene; 2000 Dec 14; 19(54):6286-96. PubMed ID: 11175343
    [Abstract] [Full Text] [Related]

  • 13. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
    Ramaraj P, Singh H, Niu N, Chu S, Holtz M, Yee JK, Bhatia R.
    Cancer Res; 2004 Aug 01; 64(15):5322-31. PubMed ID: 15289338
    [Abstract] [Full Text] [Related]

  • 14. The c-Fes protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukemia cells induced by Bcr-Abl.
    Lionberger JM, Smithgall TE.
    Cancer Res; 2000 Feb 15; 60(4):1097-103. PubMed ID: 10706130
    [Abstract] [Full Text] [Related]

  • 15. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
    Cuenco GM, Ren R.
    Oncogene; 2001 Dec 13; 20(57):8236-48. PubMed ID: 11781838
    [Abstract] [Full Text] [Related]

  • 16. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV, Gerasimova LP, Sarkisian GP, Borovkova TV, Dukhovenskaia EA, Manakova TE, Naĭdenova NM, Timofeev AM, Grineva NI.
    Tsitologiia; 2007 Dec 13; 49(10):889-900. PubMed ID: 18074781
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
    Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.
    Oncogene; 2002 Dec 12; 21(57):8804-16. PubMed ID: 12483533
    [Abstract] [Full Text] [Related]

  • 18. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
    Wang Z, Sampath J, Fukuda S, Pelus LM.
    Cancer Res; 2005 Sep 15; 65(18):8224-32. PubMed ID: 16166298
    [Abstract] [Full Text] [Related]

  • 19. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
    Hoover RR, Gerlach MJ, Koh EY, Daley GQ.
    Oncogene; 2001 Sep 13; 20(41):5826-35. PubMed ID: 11593388
    [Abstract] [Full Text] [Related]

  • 20. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
    Ahmed M, Dusanter-Fourt I, Bernard M, Mayeux P, Hawley RG, Bennardo T, Novault S, Bonnet ML, Gisselbrecht S, Varet B, Turhan AG.
    Oncogene; 1998 Jan 29; 16(4):489-96. PubMed ID: 9484838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.